Last reviewed · How we verify

NCT03856138

Effect of Gut Microbiota and Fecal Inflammatory Marker on Childhood Gastroenteritis

Completed Last updated 27 February 2019
What this trial tests

trial in Clinical Infection in 118 participants. Completed in 28 February 2018.

Timeline
1 December 2015
Primary endpoint
28 February 2018
28 February 2018

Quick facts

Lead sponsorChang Gung Memorial Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment118
Start date1 December 2015
Primary completion28 February 2018
Estimated completion28 February 2018
Sites1 location across Taiwan

Conditions studied

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 6 Months to 12, any sex, with Clinical Infection or Microbial Colonization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Childhood gastroenteritis establishes gastrointestinal disease and increase the economic burden, and the pediatric population is especially vulnerable to these gastrointestinal infections. The aim of this study is to evaluate the role of intestinal microbiota and their relationship with childhood gastroenteritis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Probiotic <i>Lactobacillus casei</i>: Effective for Managing Childhood Diarrhea by Altering Gut Microbiota and Attenuating Fecal Inflammatory Markers.
    Lai HH, Chiu CH, Kong MS, Chang CJ, et al · · 2019 · cited 83× · PMID 31126062 · DOI 10.3390/nu11051150

Verify or expand the search:

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03856138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing